News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DefiniGEN Ltd Joins European Bank For Induced Pluripotent Stem Cells (EBiSC) Consortium



8/27/2014 8:49:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

First European bank for induced pluripotent stem cells

EFPIA pharmaceutical companies, SMEs, and academia join together in an IMI supported public-private partnership project to establish the leading facility for the storage and distribution of induced pluripotent stem (iPS) cells in Europe.

Cambridge, UK, 27th August 2014: DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced it has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The EBiSC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new therapeutics. DefiniGEN’s role will be to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.

Dr Marcus Yeo, CEO of DefiniGEN, said: “We are delighted to be a part of this ground-breaking consortium which will provide a crucial platform resource to enable the realisation of the full potential of iPS technology.”

Conceptualised and coordinated by Pfizer Ltd in Cambridge, UK and managed by Roslin Cells Ltd in Edinburgh, the EBiSC bank aims to become the European ”go to” resource for high quality research grade human iPS cells. Today, iPS cells are being created in an increasing number of research programmes underway in Europe, but are not being systematically catalogued and distributed at the necessary scale to keep pace with their generation, nor to meet future demand. The €35 million project will support the initial build of a robust, reliable supply chain from the generation of customised cell lines, the specification to internationally accepted quality criteria and their distribution to any global qualified user, ensuring accessibility to consistent, high quality tools for new medicines development.

Ruth McKernan, CSO of Pfizer’s Neusentis research unit, said: “We are excited to be a part of this precompetitive collaboration to build a sustainable repository of high quality human iPS cell lines. For many areas of research in academia and in industry, understanding the biological basis of disease heterogeneity is the next horizon. A bank of well-characterised iPS lines with strong relevance to the entire research community will help us all in our mission to bring therapies to patients.”

Since their discovery by Shinya Yamanaka in 2006, iPS cells have been recognised as a break-through technology which is leading to new approaches for the development of medical therapies and for the understanding of genetic diseases. iPS cells are produced in research laboratories by “reprogramming” cells provided by individual donors with appropriate consent, typically skin or certain blood cells. The iPS cells created will then replicate indefinitely or, under controlled conditions, can be “differentiated” into any other cell type such as nerve, heart or liver cells. Researchers are able to use these cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop. iPS cells are particularly important for research on diseases for which it is not possible to obtain relevant tissue samples from living patients – such as neurodegenerative diseases including Alzheimer’s and Huntington’s Disease.

Numerous research programmes are currently underway in Europe to produce iPS cells from hundreds of different donors. Each programme has its own research goal, but as the iPS cells can be replicated to produce more cells than needed by the project, they could also be used by other researchers. However, the individual projects do not have the financial, technical or human resources to distribute cells to other researchers. This is the task which EBiSC is being established to address.

Aidan Courtney, CEO of Roslin Cells, said: “The consortium includes many of Europe’s leading stem cell scientists and experts in related fields such as data management, law and social sciences. This breadth of expertise will allow EBiSC to establish rigorous methods to ensure that the cells distributed to researchers meet internationally recognised standards and also that their use is consistent with the consent of the tissue donor and the national laws of the country in which the iPS cells were originally generated. We will keep abreast of the fast moving progress in the field of how to make these cells and also provide an on-line resource to pool the results of research undertaken with the catalogue items that we distribute. In this way, EBiSC will create an ever increasing wealth of iPS cells, data and knowledge, which will help advancing drug development and health research.”

Notes to Editors: Press contacts For DefiniGEN Lorna Cuddon, Zyme Communications Ltd Email: lorna.cuddon@zymecommunications.com Phone: +44 (0) 7811 996 942

For EBiSC Email: ebisc@eurtd.com www.ebisc.org

Project Partners

EFPIA companies
• Neusentis, a Research Unit of Pfizer Ltd, UK
• Novo Nordisk, Denmark
• AstraZeneca AB, Sweden
• H. Lundbeck A/S, Denmark
• Janssen Pharmaceutica NV, a Pharmaceutical Company of Johnson & Johnson, Belgium
• UCB Pharma SA, Belgium

SMEs • Roslin Cells Ltd, UK
• ARTTIC, France
• DefiniGEN Ltd, UK
• Douglas Connect GmbH, Switzerland
• Bioneer A/S, Denmark
• European ScreeningPort, Germany

Universities, research organisations, public bodies, non-profit groups
• University of Edinburgh, UK
• Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (Fraunhofer-Institut für Biomedizinische Technik), Germany
• Genome Research Limited (Wellcome Trust Sanger Institute), UK
• European Molecular Biology Laboratory (European Bioinformatics Institute), Germany
• Charité University Medicine Berlin, Germany
• University of Newcastle Upon Tyne, UK
• Klinikum Der Universitaet Zu Koeln, Germany
• Gottfried Wilhelm Leibniz Universitaet Hannover, Germany
• Koninklijke Nederlandse Academie van Wetenschappen (The Hubrecht Institute), The Netherlands
• University College London, UK
• Universitaetsklinikum Bonn, Germany
• Culture Collections of PHE, UK
• National Institute for Biological Standards and Control, UK
• Instituto de Salud Carlos III. (Spanish Stem Cell Bank), Spain

For further information on EBiSC and the project partners see www.ebisc.org.
For more information on the Innovative Medicines Initiative (IMI), visit www.imi.europa.eu

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is the world’s largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Innovative Medicines Initiative currently supports 40 projects, many of which are already producing impressive results. The projects all address major bottlenecks in drug development, and so will accelerate the development of safer and more effective treatments for patients. More info on IMI: www.imi.europa.eu

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com

About Roslin Cells

Roslin Cells is a leader in the development and production of stem cells for research and the production of cell therapies. The company was established at the world renowned Roslin Institute in 2006 and is now based at the Edinburgh BioQuarter where, in addition to its iPSC core facility, it operates state-of-the-art clean rooms for the production of new cell therapies. This enables the company to provide research and clinical grade iPS cell services to prominent industry, academic and clinical researchers who are breaking new ground in cellular models for research, drug discovery and also the next generation of cells to be manufactured for cellular therapies. For more information on Roslin Cells: www.roslincells.com

The EBiSC project

The EBiSC project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115582, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES